Last reviewed · How we verify
Pegasys plus Entecavir — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Pegasys plus Entecavir (Pegasys plus Entecavir) — National Taiwan University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pegasys plus Entecavir TARGET | Pegasys plus Entecavir | National Taiwan University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pegasys plus Entecavir CI watch — RSS
- Pegasys plus Entecavir CI watch — Atom
- Pegasys plus Entecavir CI watch — JSON
- Pegasys plus Entecavir alone — RSS
Cite this brief
Drug Landscape (2026). Pegasys plus Entecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/pegasys-plus-entecavir. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing